Qoliana is a drug owned by Sandoz Inc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 19, 2025. Details of Qoliana's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7265117 | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(9 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qoliana's patents.
Latest Legal Activities on Qoliana's Patents
Given below is the list of recent legal activities going on the following patents of Qoliana.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Feb, 2019 | US7265117 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Sep, 2007 | US7265117 |
| Recordation of Patent Grant Mailed Critical | 04 Sep, 2007 | US7265117 |
| Issue Notification Mailed Critical | 15 Aug, 2007 | US7265117 |
| Dispatch to FDC | 31 Jul, 2007 | US7265117 |
| Application Is Considered Ready for Issue Critical | 13 Jul, 2007 | US7265117 |
| Issue Fee Payment Received Critical | 09 Jul, 2007 | US7265117 |
| Issue Fee Payment Verified Critical | 09 Jul, 2007 | US7265117 |
| Mail Notice of Allowance Critical | 27 Jun, 2007 | US7265117 |
| Notice of Allowance Data Verification Completed Critical | 23 Jun, 2007 | US7265117 |
US patents provide insights into the exclusivity only within the United States, but Qoliana is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qoliana's family patents as well as insights into ongoing legal events on those patents.
Qoliana's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qoliana's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 19, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qoliana Generic API suppliers:
Brimonidine Tartrate is the generic name for the brand Qoliana. 13 different companies have already filed for the generic of Qoliana, with Sandoz having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Qoliana's generic
Alternative Brands for Qoliana
There are several other brand drugs using the same active ingredient (Brimonidine Tartrate) as Qoliana. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Alcon Labs Inc |
| ||
| Bausch And Lomb Inc |
| ||
| Galderma Labs Lp |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Brimonidine Tartrate, Qoliana's active ingredient. Check the complete list of approved generic manufacturers for Qoliana
About Qoliana
Qoliana is a drug owned by Sandoz Inc. Qoliana uses Brimonidine Tartrate as an active ingredient. Qoliana was launched by Sandoz in 2006.
Approval Date:
Qoliana was approved by FDA for market use on 22 May, 2006.
Active Ingredient:
Qoliana uses Brimonidine Tartrate as the active ingredient. Check out other Drugs and Companies using Brimonidine Tartrate ingredient
Dosage:
Qoliana is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.15% | SOLUTION/DROPS | Prescription | OPHTHALMIC |